Renalyx launches world’s first indigenous AI based smart hemodialysis machine
Renalyx Health Systems has unveiled RENALYX – RxT 21, the world’s first fully indigenous, AI and cloud-enabled smart hemodialysis machine. Designed to transform renal care in India, it offers real-time remote monitoring, affordability, and clinical-grade connectivity—bridging the dialysis gap for ESRD patients across urban and rural regions.
Aims to make dialysis accessible to End-Stage Renal Disease (ESRD) patients across India.
Mumbai, June 11, 2025: Renalyx Health Systems Pvt Ltd, a pioneering technology innovation company in renal care, has launched RENALYX – RxT 21, World's first fully indigenous, AI and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility. Price starting at INR 6.70 lakh – significantly lower than the imported machines – RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions.
Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues.
RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification.
Renalyx has plans to invest INR 800 crore in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also has plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand.
The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years.
With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe.
Commenting on the launch of Rx T21, Dr Shyam Vasudeva Rao, Founder & Director of Renalyx Health Systems said, “Our cutting-edge hemodialysis machine will revolutionise the renal care by making dialysis facility affordable and accessible, thus strengthening the kidney healthcare infrastructure of the country. By bringing dialysis services closer to patients’ homes, RxT 21 will help in addressing the rising Chronic Kidney Disease (CKD) burden and ESRD patients. Our indigenously developed hemodialysis machine will play a game-changing role in reducing dialysis expense, thus ensuring better healthcare impact. Going forward, we have plans to scale up our manufacturing capacity and reduce the Total Cost of Ownership of RxT 21 by 40% compared to that of imported machines. We have plans to develop a broader range of technologically advanced machines over the next three years, including a home dialysis model. In line with the government vision of ‘Make in India Make for the World’, we aim to export our machine to various countries to make a larger impact on renal care infrastructure globally. We aim to become one of the world’s leading producers and exporters within the next five years.”
The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the US FDA approval process is underway and anticipated by March 2026.
